Answers are grounded in this paper and cite their sources.
Background: Asthma is a chronic airway disease that causes patients to experience breathing difficulties together with restricted airflow. The disease causes patients to experience acute exacerbations which lead to increased healthcare costs and higher levels of illness. The current methods of predicting asthma exacerbations through symptom assessment and lung function tests face substantial difficulties. Objectives: To assess the ability of fractional exhaled nitric oxide (FeNO) in predicting future exacerbations of Asthma. To assess and compare the ability of FeNO, spirometry, and the Asthma Control Test (ACT) in predicting future exacerbations of asthma and their correlation with each other. Materials and Methods: A prospective cohort study was conducted among 86 individuals with bronchial asthma at a tertiary care center. Assessment at baseline included ACT scoring, spirometry, and FeNO levels. The patients were then followed up for the development of asthma exacerbations. The statistical analyses involved the Chi-square test and Mann–Whitney U test. P < 0.05 was used to determine statistical significance. Results: There were 26 (30.2%) cases of asthma exacerbation among the study population. Those with asthma exacerbations exhibited significantly lower ACT scores and lower Forced Expiratory Volume in one second (% predicted) values than those without exacerbations ( P < 0.001; P < 0.01, respectively). An increased level of FeNO was strongly correlated with an increased risk of future asthma exacerbations, and those with FeNO > 50 ppb were at the highest risk ( P < 0.001). In comparison with the other two assessment techniques, FeNO proved to have higher predictive value than the ACT score and spirometry parameters. Conclusion: FeNO is a strong and independent predictor of future asthma exacerbations. The combination of symptom-based assessment and spirometry fails to provide reliable prediction of exacerbation risk. The combined assessment method, which includes ACT and spirometry and FeNO measurement, establishes an asthma risk assessment and management method that offers complete and precise results.
No takes yet. Share an insight, caveat, or question.
Rohith et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: